Dr. Nanda
Dr. Nanda
Dr. Nanda
Lain-lain
• Speaker in Interactive Corner at 26th
Asmiha, 2017: STEMI in Myasthenia Gravis
Patient
• Mederator in Clinical Updates 2017
ACUTE PULMONARY
EMBOLISM
DIAGNOSIS AND CURRENT
MANAGEMENT
Epidemiology
Difficult to determine
Third most frequent
because it remain
cardiovascular disease,
asymptomatic, or first
incidence 100-200 per
presentation may be sudden
100.000 inhabitants
cardiac death
Prothrombin
gene
mutation
Deficiency of
Factor V
Antithrombin
Leiden
III, protein C
Mutation
or protein S
Inherite
d Risk
Factors
Sources of Thrombosis
Not
SPECIFIC
Haemodynamic
Consequances
Hemodynamic Status
Therapy:
Reperfusion (thrombectomy and/or thrombolysis)
• Normotensive
• Well’s Score Probability
- High CTPA
- Low/intermediate
+ D-dimer positive CTPA
Non High
Feeling defect by CTPA
Risk
sPESI
Treatment
European Heart Journal (2014) 35, 3033–3080 doi:10.1093/eurheartj/ehu283
Variables Points
Haemoptysis +1
Well’s score Heart Rate >100 beats/min +1.5
Clinical signs of DVT +3
Alternative diagnosis less likely -3
than PE
Low 0 -1
Intermediate 2 -6
High 7
PE unlikely 0-4
PE likely >4
European Heart Journal (2014) 35, 3033–3080 doi:10.1093/eurheartj/ehu283
D-dimer Test for aPE
False Positives:
•Pregnant Patients •Hemmorrhage
•Post-partum < 1 week •CVA
•Malignancy •AMI
•Surgery within 1 week •Collagen Vascular
•Advanced age > 80 years Diseases
•Sepsis •Hepatic Impairment
•DVT
aPE confirmed
(CTPA feeling
defect)
Variables Points
Age > 80 years 1
Cancer 1
Chronic Cardiopulmonary Disease
1
Saturation <90% 1
Low risk 0
Intermediate 1
sPESI
RV dysfunction
Lab Trop T or I
RV LV
Hypo kinetic
basal
Chronic RV Dysfunction by Echo
RV Hypokinetic:
LV
TAPSE < 1.6 cm
Hypo without TR
TAPSE < 2 cm with TR
kinetic
basal
Troponin T or I
• Normal:<0.02ng/mL
• Border line: 0.02 – 0.1 ng/mL serial test
Troponin I • Definitive: 0.1 ng/mL
Management
Management
Conclusion